Ibuprofen 400mg Softgel Partnership
Phase
active agreement
Deal Value
$1,500,000.00
royalty
End Date
August 31st, 2028
Key Milestone
May 31st, 2028
Project Details
Supplier
BioInnovate SolutionsLead Department
Business DevelopmentStart Date
September 1st, 2023
End Date
August 31st, 2028
Financial Terms
royalty
Renewal Term
12 months
Project ID
PXG-LIC-2023-015
Dossier Status
approved
Description
Co-development and licensing agreement for a novel softgel formulation of Ibuprofen.
Project History
Sep 1, 2023
9:00 AM
Licensing agreement signed.
Dossier Review Hub
Track due diligence progress across key departments.
Business Development
Regulatory Affairs
R&D
Supply Chain
Legal & IP
Attachments
All related documents.
No attachments found.